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Aims There is limited information on the role of screening with electrocardiography (ECG) for identifying cardiovascular





Between 2012 and 2014, 26 900 young individuals (aged 14–35 years) were prospectively evaluated with a health
questionnaire and ECG. Individuals with abnormal results underwent secondary investigations, the costs of which
were being based on the UK National Health Service tariffs. Six hundred and seventy-five (2.5%) individuals re-
quired further investigation for an abnormal health questionnaire, 2175 (8.1%) for an abnormal ECG, and 114
(0.5%) for both. Diseases associated with young SCD were identified in 88 (0.3%) individuals of which 15 (17%)
were detected with the health questionnaire, 72 (81%) with ECG and 2 (2%) with both. Forty-nine (56%) of these
individuals received medical intervention beyond lifestyle modification advice in the follow-up period of 24 months.
The overall cost of the evaluation process was e97 per person screened, e17 834 per cardiovascular disease
detected, and e29 588 per cardiovascular disease associated with SCD detected. Inclusion of ECG was associated
with a 36% cost reduction per diagnosis of diseases associated with SCD compared with the health questionnaire
alone.
...................................................................................................................................................................................................
Conclusion The inclusion of an ECG to a health questionnaire is associated with a five-fold increase in the ability to detect dis-
ease associated with SCD in young individuals and is more cost effective for detecting serious disease compared
with screening with a health questionnaire alone.
* Correspondence author. Tel: þ44 2087255939; fax: þ44 2087253328. E-mail address: sasharma@sgul.ac.uk
† These authors contributed equally to the study.
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stricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Introduction
Most sudden cardiac deaths (SCD) in young individuals are due to he-
reditary or congenital heart diseases that are detectable during life
and the natural history and risk posed by these diseases can be modi-
fied through several established medical interventions. Evidence for
the efficacy of cardiovascular screening to identify young individuals
with cardiac disease associated with SCD is derived exclusively from
young competitive athletes.1,2 Although the incidence of SCD in
young athletes is higher than in non-athletes, the ethics of limiting car-
diac screening to competitive athletes are questionable because non-
athletes represent a significantly larger group in whom the absolute
number of deaths is higher than in athletes.3,4 The National Health
Service (NHS) in the UK acknowledges the importance of identifying
all young individuals at risk of SCD, however, cardiovascular evalua-
tion is currently limited to those reporting symptoms or a family his-
tory of cardiovascular disease and those with abnormal findings
during incidental cardiovascular examination.5 In this first study of its
kind, we sought to determine the diagnostic yield and actual financial
cost incurred to detect cardiovascular disease through electrocardi-
ography (ECG) screening in a nationwide screening programme in
young individuals in the UK.
Methods
Setting
The charitable organisation Cardiac Risk in the Young (CRY) facilitates
screening for diseases predisposing to SCD in young individuals (aged
14–35 years-old). Such evaluations are accessible to all individuals, irre-
spective of athletic status, symptoms, or family history of premature car-
diac disease. Screening events are advertised in the local media and on
the CRY website (www.c-r-y.org). Individuals from the general popula-
tion self-present to screening events. The evaluations and their reporting
are the overall responsibility of the senior author.
Subjects
Between 2012 and 2014, 27 458 consecutive individuals aged 14–
35 years-old self-presented for cardiovascular evaluation comprising a
health questionnaire and 12-lead ECG which was conducted by
What’s new?
• This is the first study to report the results of an
electrocardiogram-based cardiovascular screening programme
in the young general population at a nationwide level.
• The prevalence of cardiovascular disease associated with
young sudden cardiac death in the general population is 0.3%.
• The cost of electrocardiogram-based cardiovascular screening
is e97 per person screened, e17 834 per cardiovascular
disease detected and e29 588 per cardiovascular disease
associated with sudden cardiac death detected.
• Inclusion of an electrocardiogram to the current practice of
symptom and family history driven evaluation increases the
diagnostic yield for serious cardiac disease by five-fold and is
associated with a 36% reduction in cost per disease detected.
• Most young individuals identified with serious cardiac disease
(including those who are asymptomatic and have no worrying
family history) received disease modifying therapy within 2
years of detection through screening.
Graphical Abstract
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cardiologists experienced in inherited cardiac diseases. Five hundred and
fifty-eight (2%) individuals were excluded due to a pre-existing cardiac di-
agnosis or prior cardiovascular assessment within the past 2 years leaving




The health questionnaire enquired about cardiac symptoms, past medical
history, and family history of premature (<50 years old) cardiac disease
or SCD (Supplementary material online, Figure S1).
Electrocardiography
A resting 12-lead ECG was performed using a Philips Pagewriter Trim III
recorder (Philips, Bothell, WA, USA) with a paper speed of 25 mm/s and
amplification of 0.1 mV/mm. The absolute QT was corrected for heart
rate using the Bazett’s formula.6 The Fredericia formula was used at
extremes of heart rate. The European Society of Cardiology (ESC) rec-
ommendations were used to interpret the ECG as these were derived
from 30 000 young individuals who were screened before entering com-
petitive sport and resembled our cohort most closely.7 We used slightly
longer QT interval cut-offs (>460 ms) as our previous experience has
shown that 6.5% of the young non-athlete cohort has a QT above 440 ms
in males and 460 ms in females.8 We also used a more stringent cut-off of
<330 ms to define a short QT interval.9
Further investigations and disease
identification
Further investigations were determined by the screening cardiologists.
Individuals requiring secondary investigations were referred to local hos-
pitals through their primary care physician with a report that specified the
abnormal findings, copy of the ECG, diagnosis in question, and a pro-
posed investigation protocol based on our experience of investigating
athletes and young individuals with cardiovascular disease.
Secondary investigations were conducted by local cardiologists who
also determined the type and number of secondary investigations. Data
relating to secondary investigations and the final diagnosis were obtained
from the primary care physician 24 months following the initial evaluation.
Diseases considered to be associated with SCD were as previously
reported.10,11
Financial analysis
Costs were incurred in British pounds (£) but presented as Euros (e) at a
conversion rate of £1=e1.13 at the time of the manuscript was prepared.
The initial investigations (health questionnaire and ECG) were performed
at a subsidized cost of e57 per individual. The cost of secondary investiga-
tions was based on the UK National Health Service tariff payment system
(www.england.nhs.uk/pay-syst/national-tariff) (Supplementary material
online, Table S1). There is no national rebate for pharmacological testing
for Brugada syndrome, tilt table testing, 24-h blood pressure monitoring,
or signal average ECG, therefore, we used the fee for these procedures
at our institute for the analysis. The fees for genetic testing were derived
from the NHS UK genetic testing network.
Estimation of cost with a health questionnaire only
strategy
When estimating the costs of the health questionnaire only strategy, we
assumed an initial screening cost of e17, after accounting for the cost of
ECG in the NHS (e40).
Statistical analysis
Statistical analysis was performed using SPSS. Results are reported as
mean ± SD for continuous variables or numbers of cases and percentages
for categorical variables with 95% confidence intervals as appropriate.
Comparison of groups was performed using the Student’s t-test for con-
tinuous variables with correction for unequal variance when necessary
and v2 test or Fisher’s exact test, as appropriate for categorical variables.
Cohen’s kappa (j) coefficient was used to calculate the inter-observer
agreement in ECG interpretation.
Ethics
Ethical approval was granted by the Essex 2 Research Ethical Committee.
Written consent was obtained from individuals >_16 years of age and
from a parent/guardian for those <16 years of age.
....................................................................................................................................................................................................................






Chest pain 753 (2.7) 31 (0.1)
Palpitations 1141 (4.2) 79 (0.3)
Syncope/pre-syncope 1790 (6.7) 62 (0.2)
Excessive exertional and unexplained fatigue/
dyspnoea
506 (1.8) 58 (0.2)
>_1 of above symptoms 642 (2.4) 211 (0.8)
Total 4832 (17.9) 441 (1.6)
Family history
Premature death—sudden and unexpected be-
fore age 50 years due to heart disease, in one
or more relatives
426 (1.6) 189 (0.7)
Specific knowledge of certain cardiac condi-
tions in family members
429 (1.6) 219 (0.8)
Total 855 (3.2) 408 (1.5)
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Results
Study participants
Individuals were aged 19.4± 4 years. The majority were male
(n = 17 530; 65%) and white (n = 24 299; 90%). Five hundred and
forty-six (2%) were of African or Afro-Caribbean origin and 2055
(8%) consisted of other ethnicities. The cohort exercised for
3.9 ± 3.0 h/week. Most (81%) evaluations were undertaken in
England including 43 of the 48 lieutenancy counties, 13% in Northern
Ireland, 3% in Scotland, and 3% in Wales. Evaluations took place in
214 different venues and occurred predominantly at community
centres (71.9%), but also in high schools (19.5%) and healthcare pro-
vider centres (hospitals and family practice centres) (8.6%).
Health questionnaire and
electrocardiographic abnormalities
Five thousand four hundred and seventy three [20.4% (95% CI 19.9–
20.8%)] individuals reported cardiac symptoms [n = 4618 (17.2%)], a
family history of cardiovascular disease or premature death [n = 641
(2.4%)], or both [n = 214 (0.8%)] (Table 1). Following consultation
with the screening cardiologist, the number considered to have
symptoms compatible with cardiac disease and those considered to
have a family history suggestive of an inherited cardiac disease was re-
duced to 381 (1.4%) and 348 (1.3%), respectively. A random sample
of 2500 ECGs was reported by two cardiologists blind to other clini-
cal details, with good inter-observer agreement [j = 0.62 (95% CI
0.54–0.70)] for classifying an ECG as abnormal. Sixty (0.2%) individu-
als had abnormal symptoms and family history. An abnormal ECG
was noted in 2289 [8.5% (95% CI 8.1–8.9%)] individuals (Table 2).
Follow-up and further investigations
Following preliminary evaluation, 2964 [11.0% (95% CI 10.5–11.6%)]
individuals required further investigation including 675 (2.5%) for an
abnormal health questionnaire, 2175 (8.1%) for an abnormal ECG,
and 114 (0.4%) for both.
Follow-up information pertaining to secondary investigations and
diagnoses was available in 2917 (98.5%) individuals. Twenty-five cases
with an abnormal health questionnaire and 22 with an abnormal ECG
were lost to follow-up.
Transthoracic echocardiography was performed in 2860 (10.6%)
individuals, 483 (1.8%) underwent exercise stress testing, 486 (1.8%)
underwent Holter monitoring, and 233 (0.9%) underwent cardiac
magnetic resonance imaging (Supplementary material online, Table
S2). Additionally, 115 (0.4%) individuals underwent a combination of
24-h blood pressure monitoring, signal average ECG, tilt table testing
electrophysiological studies, trans-oesophageal echocardiography,
computed tomography, myocardial perfusion scanning, or pharmaco-
logical provocation testing for Brugada syndrome to confirm (or re-
fute) diagnosis of cardiac disease.
Detection of cardiovascular disease
Cardiovascular disease associated with sudden cardiac
death
Cardiac disease potentially associated with SCD was detected in 88
[0.3% (95% CI 0.2–0.4%)] individuals (Figure 1 and Supplementary ma-
terial online, Table S3). Ventricular pre-excitation [n = 42 (48%)], hy-
pertrophic cardiomyopathy [n = 14 (16%)], long QT syndrome
[n = 10 (11%)], and Brugada syndrome [n = 8 (9%)] were the most
common diagnoses. The other 14 (16%) diseases included Marfan
syndrome (n = 3), arrhythmogenic right ventricular cardiomyopathy
(n = 3), dilated cardiomyopathy (n = 3), left ventricular non compac-
tion cardiomyopathy (n = 2), catecholaminergic polymorphic ventric-
ular tachycardia (n = 2), and congenital complete heart block (n = 1)
(Supplementary material online, Table S3). Fifteen (17%) cases were
identified by the health questionnaire, 2 (2%) by health questionnaire
and ECG, and 71 (81%) solely by ECG (Figure 1).
The diagnosis of a long QT syndrome (n=9) following assessment
for a prolonged QT was based of a Schwartz score >_3.5.12 All eight
cases of Brugada syndrome had a normal baseline ECG and required
with an ajmaline provocation test to investigate a family history of
Brugada syndrome in a first-degree relative, or SCD. None of the five
individuals with a short QT interval were diagnosed with short QT
syndrome based on the absence of symptoms, family history, or car-
diac arrhythmias during an exercise test or 24-h Holter monitoring
period.13
....................................................................................................................................................................................................................
Table 2 ECG abnormalities
ECG abnormality Frequency (%) ECG abnormality Frequency (%)
>_1 ECG abnormality 2289 (8.5) Non-specific intraventricular con-
duction delay
117 (0.4)
T-wave inversion 1062 (3.9) Right bundle branch block 34 (0.1)
ST depression 30 (0.1) Left bundle branch block 3 (0.01)
Q-waves 49 (0.2) Long QT interval 444 (1.6 )
Right axis deviation 298 (1.1) Short QT interval 5 (0.02)
Left axis deviation 371(1.4) Pre-excitation 42 (0.2)
Right atrial enlargement 71 (0.3) Ventricular ectopy 113 (0.4)
Left atrial enlargement 111 (0.4) Atrial arrhythmia 6 (0.02)
Right ventricular hypertrophy 107 (0.4) Significant bradyarrhythmia 10 (0.04)
ECG, electrocardiography.
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Other cardiovascular disease
Congenital valvular and septal defects were detected in 58 [0.2%
(95% CI 0.2–0.3%)] individuals (Supplementary material online, Table
S4). Of these, 20 (35%) individuals reported symptoms , 3 (5%)
reported symptoms and had an abnormal ECG, and 35 (60%) were
asymptomatic but had an abnormal ECG.
In total, a cardiovascular disorder was detected in 146 [0.5% (95%
CI 0.5–0.6%)] individuals of which 35 (24%) were identified by the
health questionnaire, 5 (3%) by a combination of the health question-
naire and ECG, and 106 (73%) by ECG alone (Figure 1).
Management of individuals identified
with potentially serious cardiac disease
During the 24-month follow-up period after screening, 49/88 (56%)
individuals diagnosed with potentially serious cardiac disease through
the screening programme received >_1 medical intervention beyond
lifestyle advice (Supplementary material online, Table S3). Specifically,
22/88 (25%) were prescribed pharmacotherapy, 3/88 (3%) received
an implanted cardiac device [pacemaker/implantable cardioverter-
defibrillator (ICD)] and 26/88 (30%) underwent ablation.
Medical intervention was implemented in 42/71 (59%) asymptom-
atic individuals with potentially serious cardiac disease diagnosed
solely on the basis of an abnormal ECG. This included two patients
who received an ICD for primary prevention during the follow-up
period (one patient with arrhythmogenic right ventricular cardiomy-
opathy and one patient with left ventricular non-compaction
cardiomyopathy).
Financial analysis
Total cost of the screening programme
The overall cost of the programme was e2 603 742, equating to a
cost of e97 per person screened, e17 834 per cardiovascular disease
detected, and e29 588 per cardiac disease associated with SCD
detected (Table 3).
Estimated cost of health questionnaire only screening
strategy
Based on the preliminary evaluation cost of e17 for a health question-
naire, and costs of subsequent investigations following consultation
with a cardiologist, the overall cost of screening with a health ques-
tionnaire only strategy would have amounted to e784 739 at a cost
of e29 per person screened (Table 3). This strategy would have iden-
tified 40/146 (27%) individuals with all cardiovascular diseases at a
cost of e19 618 per disease, and 17/88 (19%) individuals with cardiac
disease associated with SCD at a cost of e46 161 per disease.
Discussion
Principle findings
We evaluated the diagnostic yield and financial implications of a car-
diovascular screening programme comprising of a health question-
naire and 12-lead ECG in almost 27 000 predominantly
asymptomatic young individuals in the UK. Subsequent investigations
led to the detection of cardiovascular abnormalities in 146 (0.5%)
individuals, including 88 (0.3%) with diseases associated with SCD.
As far as we are aware, this is the first study to report the preva-
lence of cardiovascular disease in the young general population at na-
tionwide level. These results are comparable to the prevalence of
diseases reported by cardiovascular screening programmes in com-
petitive athletes.14–16 This finding is not surprising as most of the dis-
eases capable of causing SCD in young individuals have a genetic or
congenital basis and do not have a unique predilection for competi-
tive sport.
Figure 1 Method of disease detection through cardiovascular screening. Overall, 73% of all diseases and 81% of diseases associated with sudden
cardiac death were identified on the basis of an ECG abnormality in asymptomatic individuals with a normal family history. SCD, sudden cardiac
death; ECG, electrocardiography.
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This is also the first study to report the actual financial cost in-
curred to detect cardiovascular disease through ECG screening in a
nationwide program, which amounts to e97 per person screened,
e17 834 per cardiovascular disease detected, and e29 588 per cardiac
disease associated with SCD detected.
Disease detection and impact on
management
The majority [61/88 (69%)] of diseases identified by screening [in-
cluding 49/71 (69%) those detected solely on the basis of an abnor-
mal ECG ] were hereditary ion channel diseases or congenital
accessory pathways. These conditions are characteristically associ-
ated with a structurally normal heart at post-mortem and hence may
have important clinical significance since unexplained SCD with a
normal macroscopic and histological appearance of the heart at post-
mortem is the leading cause of SCD in young individuals.10,11,17
The identification of individuals with diseases associated with SCD
through screening has the potential for several other interventions
and risk stratification to minimize the risk of sudden cardiac arrest. In
this study, early medical intervention beyond lifestyle modification
was implemented in over half of the individuals diagnosed with dis-
ease associated with SCD, including 60% of those identified solely
on the basis of an abnormal ECG (Supplementary material online,
Table S3). Although only two individuals in the study received an ICD
in the short follow-up period, the early identification of disease offers
the opportunity for closer clinical surveillance and escalation of treat-
ment in the event of developing high-risk factors in the future.
Study implications
Cardiovascular evaluation for young individuals in the UK and most
western countries is limited to the minority with symptoms or a fam-
ily history suggestive of cardiovascular disease. In this study, 73% of all
individuals with cardiac disease and 81% diagnosed with diseases as-
sociated with SCD were asymptomatic or, did not have a relevant
family history and would not have been identified through the current
healthcare policy (Figure 1). Although the overall cost of screening
with the ECG is higher, this strategy was associated with a 9% lower
cost per all cardiovascular disease detected and a 36% lower cost per
cardiac disease associated with SCD detected when compared with
screening with the health questionnaire only strategy (Table 3).
These findings are likely to have important implications for health
policy makers when considering optimal strategies to identify young
and apparently healthy individuals with potentially serious cardiac dis-
eases. The results are also significant for physicians as they highlight
the diagnostic limitations and potential cost inefficiencies of reliance
on symptoms or a family history when deciding to investigate young
individuals for cardiac disease.
Healthcare analytic perspective
It is important to highlight that the financial aspect of this study is lim-
ited solely to the cost of disease detection and not on cost-
effectiveness of ECG screening in preventing SCD. The aim of our
study was to provide a reference for the diagnostic yield and subse-
quent costs of confirming a serious cardiac diagnosis. It could be ar-
gued that the priority of any healthcare system is to focus largely on
the highest risk groups. In the Western world, most cardiovascular
deaths occur in individuals above 50 years old and are due to athero-
sclerotic coronary artery disease and heart failure. Therefore, a
screening cost of e97 per person for all adolescents and young adults
(total number of 16.7 million persons in the UK age 14–35 equating
to a cost of e1.62 billion) may be considered as excessive when only
0.5% of all young SCDs occur in this population. Conversely, early
identification of a young person with serious cardiac disease has the
potential for saving several decades of life through relatively minimal
intervention.
Limitations
This study has several limitations. Investigation beyond preliminary
screening was limited to individuals with abnormal symptoms, family
history, or ECG; therefore, we could not calculate the sensitivity or
specificity of the programme for detecting cardiac disease. We did
not perform cardiovascular examination on our patients, therefore
we may have failed to detect a number of patients with congenital val-
vular abnormalities; however current literature suggests that physical
examination is associated with a low diagnostic yield especially in
young individuals harbouring diseases associated with SCD.14,18 As
with any voluntary screening programme, there is the potential for in-
herent selection bias; however, this is partly mitigated by the large
....................................................................................................................................................................................................................
Table 3 Summary of cost incurred to identify cardiovascular disease
Cost Health Questionnaire and ECG (e) Health Questionnaire only (e)a
Screening cost (n = 26 900) 1, 533, 300 457, 300
Cost of additional Investigations following screening
HQ abnormalities (n = 675) 266, 740 (95% CI 227, 012–328, 427) 266, 740 (95% CI 227,012–328, 427)
HQ and ECG abnormalities (n = 114) 60, 699 (95% CI 40, 251–91, 313) 60, 699 (95% CI 40, 251–91, 313)
ECG abnormalities (n = 2175) 743, 003 (95% CI 700, 492–791, 632) N/A
Total cost 2 603 742 (95% CI 2 501 055–2 744 672) 784, 739 (95% CI 724, 563–877, 040)
Cost per person screened 97 (95% CI 93–102) 29 (95% CI 27–33)
Cost per cardiovascular disease detected 17, 834 (95% CI 17, 131–18, 799) 19, 618 (95% CI 18, 114–21, 926)
Cost per cardiovascular disease associated with SCD detected 29, 588 (95% CI 28, 421–31, 189) 46, 161 (95% CI 42, 621–51, 591)
aEstimated cost.
ECG, electrocardiography; HQ, health questionnaire; SCD, sudden cardiac death.
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population size and the nationwide enrolment. The cost analysis was
based on a subsidized preliminary assessment and relatively modest
costs of secondary investigations in the UK National Health Service
which are cheaper than other European and North American health-
care models. Screenings were conducted by cardiologists who were
highly experienced in inherited cardiac diseases hence there is a pos-
sibility that the proportion of individuals referred for further evalua-
tion was lower than if they had been conducted by less experienced
healthcare providers. Secondary investigations were at the discretion
of the attending cardiologist and may have been influenced by per-
sonal clinical practice as with any real-life clinical situation. Finally, the
diagnostic yield of serious disease was probably underestimated due
to the inherent limitations of the resting ECG for identifying anoma-
lous coronary origins, premature atherosclerotic coronary artery dis-
ease, adrenergically mediated arrhythmias, concealed accessory
pathways, and incomplete expressions of cardiomyopathy.19
Conclusions
The prevalence of diseases associated with young SCD identified
through a cardiovascular screening programme in the general popula-
tion is 0.3% at a cost of e29 588 per disease detected. The addition of
the ECG to health questionnaire improves the ability to detect dis-
ease associated with SCD by five-fold, with the majority receiving dis-
ease modification therapy within 2 years of diagnosis.
Supplementary material
Supplementary material is available at Europace online.
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Upon the original publication of this article, there was an error in the spelling of Co-author Gherardo Finocchiaro’s name. The full name
should read: “Gherardo Finocchiaro” instead of “Gherardo Finnochiaro”. This error has now been corrected.
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